Imatinib Grindeks

Imatinib, the active ingredient in Imatinib Grindeks, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients. It is indicated for chronic or accelerated phase CML and for unresectable or metastatic GIST.

GNH USA supplies Imatinib Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on consistent quality, regulatory adherence, and reliable cold‑chain logistics where required.

Imatinib is a targeted therapy that inhibits oncogenic tyrosine‑kinase pathways in specific hematologic and solid tumours.

Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. Gastrointestinal stromal tumor (GIST): blocks tumor growth in unresectable or metastatic disease. Philadelphia‑positive acute lymphoblastic leukemia (Ph+ ALL): provides targeted inhibition as part of combination regimens.

Imatinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting - Fluid retention and peripheral edema - Muscle cramps or weakness - Fatigue - Diarrhoea - Rash or mild skin irritation

Serious or Rare Side Effects: - Severe neutropenia or thrombocytopenia - Hepatotoxicity with elevated transaminases - Cardiac failure or reduced left‑ventricular function - Pulmonary arterial hypertension - Severe skin reactions such as Stevens‑Johnson syndrome - Life‑threatening hemorrhage

Before initiating therapy, clinicians should evaluate baseline organ function and potential risk factors. - Hepatic impairment: consider dose reduction and monitor liver enzymes. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Cardiac assessment: evaluate ejection fraction in patients with pre‑existing heart disease. - Hypersensitivity: discontinue if signs of an allergic reaction appear. - Pregnancy and lactation: discuss potential fetal risks and advise against breastfeeding while on therapy. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Imatinib may interact with several medicines that alter its plasma concentration or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) – may increase toxicity. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin) – may reduce efficacy. - Antacids containing aluminum or magnesium – can lower oral absorption.

Moderate Interactions (Monitor Closely): - Warfarin – may enhance anticoagulant effect; monitor INR. - Loop diuretics – increased risk of fluid retention. - Live vaccines – reduced immunogenicity; consider timing of vaccination.